Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HPTN 091: Integrating HIV Prevention and Gender-Affirmative Care for Transgender Women
NCT04742491Phase 3Completed
- Sponsor
- HIV Prevention Trials Network
- Start
- Mar 2021
- Primary completion
- Aug 2024
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 3 trial of tenofovir alafenamide, emtricitabine + tenofovir disoproxil in human immunodeficiency virus infection (HIV), sponsored by HIV Prevention Trials Network. Started Mar 2021; status: completed.
02
Drugs
tenofovir alafenamideemtricitabine + tenofovir disoproxil
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT04742491.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04742491.